{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:02:29Z","timestamp":1792609349505,"version":"4.5.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"22","license":[{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100008335","name":"Academy of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008335","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institute of Health\/National Cancer Institute Cancer Center","doi-asserted-by":"publisher","award":["P30CA008748)"],"award-info":[{"award-number":["P30CA008748)"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008052","name":"Alfonso Martin Escudero","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL130539, R01HL137562, K24HL150238"],"award-info":[{"award-number":["R01HL130539, R01HL137562, K24HL150238"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Chimeric antigen receptor T-cell therapy (CAR-T) harnesses a patient\u2019s immune system to target cancer. There are sparse existing data characterizing death outcomes after CAR-T-related cardiotoxicity. This study examines the association between CAR-T-related severe cardiovascular events (SCE) and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>From a multi-centre registry of 202 patients receiving anti-CD19 CAR-T, covariates including standard baseline cardiovascular and cancer parameters and biomarkers were collected. Severe cardiovascular events were defined as a composite of heart failure, cardiogenic shock, or myocardial infarction. Thirty-three patients experienced SCE, and 108 patients died during a median follow-up of 297 (interquartile range 104\u2013647) days. Those that did and did not die after CAR-T were similar in age, sex, and prior anthracycline use. Those who died had higher peak interleukin (IL)-6 and ferritin levels after CAR-T infusion, and those who experienced SCE had higher peak IL-6, C-reactive protein (CRP), ferritin, and troponin levels. The day-100 and 1-year Kaplan\u2013Meier overall mortality estimates were 18% and 43%, respectively, while the non-relapse mortality (NRM) cumulative incidence rates were 3.5% and 6.7%, respectively. In a Cox model, SCE occurrence following CAR-T was independently associated with increased overall mortality risk [hazard ratio (HR) 2.8, 95% confidence interval (CI) 1.6\u20134.7] after adjusting for age, cancer type and burden, anthracycline use, cytokine release syndrome grade \u2265 2, pre-existing heart failure, hypertension, and African American ancestry; SCEs were independently associated with increased NRM (HR 3.5, 95% CI 1.4\u20138.8) after adjusting for cancer burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Chimeric antigen receptor T-cell therapy recipients who experience SCE have higher overall mortality and NRM and higher peak levels of IL-6, CRP, ferritin, and troponin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehad117","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T12:07:51Z","timestamp":1679314071000},"page":"2029-2042","source":"Crossref","is-referenced-by-count":55,"title":["Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients"],"prefix":"10.1093","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6938-1321","authenticated-orcid":false,"given":"Syed S","family":"Mahmood","sequence":"first","affiliation":[{"name":"Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Weill Cornell Medicine , 520 East 70th Street. ST 443, New York, NY 10021 , USA"},{"name":"Cardiology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A","family":"Riedell","sequence":"additional","affiliation":[{"name":"The David and Etta Jonas Center for Cellular Therapy, University of Chicago , Chicago, IL 60637 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Feldman","sequence":"additional","affiliation":[{"name":"Cardiology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"George","sequence":"additional","affiliation":[{"name":"Cornell MPH Program, Cornell University , Ithaca, NY 14853 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A","family":"Sansoterra","sequence":"additional","affiliation":[{"name":"Cornell MPH Program, Cornell University , Ithaca, NY 14853 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Althaus","sequence":"additional","affiliation":[{"name":"The David and Etta Jonas Center for Cellular Therapy, University of Chicago , Chicago, IL 60637 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahin","family":"Rehman","sequence":"additional","affiliation":[{"name":"Cardiology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mead","sequence":"additional","affiliation":[{"name":"Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E","family":"Liu","sequence":"additional","affiliation":[{"name":"Cardiology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B","family":"Devereux","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Weill Cornell Medicine , 520 East 70th Street. ST 443, New York, NY 10021 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W","family":"Weinsaft","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Weill Cornell Medicine , 520 East 70th Street. ST 443, New York, NY 10021 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon","family":"Kim","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Weill Cornell Medicine , 520 East 70th Street. ST 443, New York, NY 10021 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Balkan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medicine , New York, NY 10021 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Barbar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medicine , New York, NY 10021 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Lee Chuy","sequence":"additional","affiliation":[{"name":"Cardiology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhisham","family":"Harchandani","sequence":"additional","affiliation":[{"name":"Cardiology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"Adult BMT Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065 , USA"},{"name":"Department of Medicine, Weill Cornell Medicine , New York, NY 10021 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark B","family":"Geyer","sequence":"additional","affiliation":[{"name":"Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065 , USA"},{"name":"Department of Medicine, Weill Cornell Medicine , New York, NY 10021 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae H","family":"Park","sequence":"additional","affiliation":[{"name":"Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065 , USA"},{"name":"Department of Medicine, Weill Cornell Medicine , New York, NY 10021 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Lia","family":"Palomba","sequence":"additional","affiliation":[{"name":"Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065 , USA"},{"name":"Department of Medicine, Weill Cornell Medicine , New York, NY 10021 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Shouval","sequence":"additional","affiliation":[{"name":"Adult BMT Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065 , USA"},{"name":"Department of Medicine, Weill Cornell Medicine , New York, NY 10021 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana A","family":"Tomas","sequence":"additional","affiliation":[{"name":"Adult BMT Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan L","family":"Shah","sequence":"additional","affiliation":[{"name":"Adult BMT Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065 , USA"},{"name":"Department of Medicine, Weill Cornell Medicine , New York, NY 10021 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric H","family":"Yang","sequence":"additional","affiliation":[{"name":"UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine, University of California at Los Angeles , Los Angeles, CA 90095 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria L","family":"Gaut","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of California Los Angeles , Los Angeles, CA 90095 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael V","family":"Rothberg","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine, University of California at Los Angeles , CA 90095 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn M","family":"Horn","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Weill Cornell Medicine , 520 East 70th Street. ST 443, New York, NY 10021 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Leonard","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine , New York, NY 10021 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Van Besien","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine , New York, NY 10021 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J","family":"Frigault","sequence":"additional","affiliation":[{"name":"Cellular Immunotherapy Program, Division of Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 , USA"},{"name":"Division of Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengming","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medicine, New York Presbyterian Hospital , New York, NY 10021 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhoomi","family":"Mehrotra","sequence":"additional","affiliation":[{"name":"The Cancer Center, St Francis Hospital , Roslyn, NY 11576 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas G","family":"Neilan","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital , Boston, MA 02114 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M","family":"Steingart","sequence":"additional","affiliation":[{"name":"Cardiology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY 10065 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,20]]},"reference":[{"key":"2023060918362027900_ehad117-B1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"2023060918362027900_ehad117-B2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"2023060918362027900_ehad117-B3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"2023060918362027900_ehad117-B4","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/eurheartj\/ehac106","article-title":"Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies","volume":"43","author":"Totzeck","year":"2022","journal-title":"Eur Heart J"},{"key":"2023060918362027900_ehad117-B5","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","author":"Melenhorst","journal-title":"Nature"},{"key":"2023060918362027900_ehad117-B6"},{"key":"2023060918362027900_ehad117-B7","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"2023060918362027900_ehad117-B8","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2021","journal-title":"N Engl J Med"},{"key":"2023060918362027900_ehad117-B9","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023060918362027900_ehad117-B10","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","article-title":"Chimeric antigen receptor T-cell therapy associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"key":"2023060918362027900_ehad117-B11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","article-title":"Cardiovascular effects of CAR T cell therapy: a retrospective study","volume":"2","author":"Lefebvre","year":"2020","journal-title":"JACC CardioOncol"},{"key":"2023060918362027900_ehad117-B12","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","article-title":"Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy","volume":"78","author":"Goldman","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023060918362027900_ehad117-B13","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2021.280009","article-title":"Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma","volume":"107","author":"Steiner","year":"2022","journal-title":"Haematologica"},{"key":"2023060918362027900_ehad117-B14","doi-asserted-by":"crossref","first-page":"A10135","DOI":"10.1161\/circ.144.suppl_1.10135","article-title":"Cardiotoxicity and mortality in chimeric antigen receptor T cell therapy recipients","volume":"144","author":"Mahmood","year":"2021","journal-title":"Circulation"},{"key":"2023060918362027900_ehad117-B15","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.jacc.2019.10.049","article-title":"Chimeric antigen receptor T-cell therapy for cancer and heart: JACC council perspectives","volume":"74","author":"Ganatra","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023060918362027900_ehad117-B16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023060918362027900_ehad117-B17","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2023060918362027900_ehad117-B18","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"2023060918362027900_ehad117-B19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2023060918362027900_ehad117-B20","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaccao.2020.08.014","article-title":"Cardiac biomarkers during cancer therapy","volume":"2","author":"Alvarez-Cardona","year":"2020","journal-title":"JACC CardioOncol"},{"key":"2023060918362027900_ehad117-B21","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J Clin Oncol"},{"key":"2023060918362027900_ehad117-B22","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"2023060918362027900_ehad117-B23","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jacc.2020.12.034","article-title":"Patient characteristics and clinical outcomes of type 1 versus type 2 myocardial infarction","volume":"77","author":"McCarthy","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023060918362027900_ehad117-B24","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"2023060918362027900_ehad117-B25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaccao.2021.01.004","article-title":"Myocarditis surveillance with high-sensitivity troponin I during cancer treatment with immune checkpoint inhibitors","volume":"3","author":"Waliany","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2023060918362027900_ehad117-B26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jaccao.2020.12.001","article-title":"Management of immune checkpoint inhibitor-induced myocarditis: the French Working Group\u2019s plea for a pragmatic approach","volume":"3","author":"Thuny","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2023060918362027900_ehad117-B27","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1200\/OP.20.00924","article-title":"Monitoring for chemotherapy-related cardiotoxicity in the form of left ventricular systolic dysfunction: a review of current recommendations","volume":"17","author":"Stone","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"2023060918362027900_ehad117-B28","author":"Herceptin (trastuzumab) Label"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/22\/2029\/50563892\/ehad117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/22\/2029\/50563892\/ehad117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T14:37:17Z","timestamp":1686321437000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/44\/22\/2029\/7081133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":28,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2023,3,20]]},"published-print":{"date-parts":[[2023,6,9]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehad117","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,7]]},"published":{"date-parts":[[2023,3,20]]}}}